The United States’ global edge in medical innovation is slipping because the discovery and development process takes too much time and money, according to a report released January 29 by Sen Lamar Alexander (R, Tenn) and Sen Richard Burr (R, NC) (http://1.usa.gov/162Tm36).
One of the main reasons for the delay in getting treatments to patients is an overburdened FDA that can’t keep up with the fast pace of biomedical innovation, Alexander and Burr said in the report.
Rubin R. Outdated Regulatory Processes Delay New Treatments, Senators Say. JAMA. 2015;313(10):1004. doi:10.1001/jama.2015.0940